A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer

The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.

Inclusion Criteria:

• Measurable disease with diagnosis of Small Cell Lung Cancer.
• Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance status schedule.
• Patients must be at least 18 years of age and have at least a 12-week life expectancy.
• No prior chemotherapy and/or prior thoracic radiotherapy.
• Adequate pulmonary function and organ function.

Exclusion Criteria:

• Patients with myocardial infarction within the preceding six months.
• Diagnosis of a serious concomitant systemic disorder.
• Prior radiotherapy to the lower neck or abdominal region.
• Significant weight loss.
• Concurrent administration of any other antitumor therapy.